Comparative Radioimmunotherapy of Experimental Melanoma with Novel Humanized Antibody to Melanin Labeled with 213Bismuth and 177Lutetium

Comparative Radioimmunotherapy of Experimental Melanoma with Novel Humanized Antibody to Melanin Labeled with 213Bismuth and 177Lutetium

Melanoma is a cancer with increasing incidence and there is a need for alternatives to immunotherapy within effective approaches to treatment of metastatic melanoma. We performed comparative radioimmunotherapy (RIT) of experimental B16-F10 melanoma with novel humanized IgG to melanin h8C3 labeled wi...

Full description

Bibliographic Details
Main Authors:	Kevin J. H. Allen, Rubin Jiao, Mackenzie E. Malo, Connor Frank, Darrell R. Fisher, David Rickles, Ekaterina Dadachova
Format:	Article
Language:	English
Published:	MDPI AG 2019-07-01
Series:	Pharmaceutics
Subjects:	radioimmunotherapy humanized antibody melanin B16-F10 melanoma 213Bismuth 177Lutetium
Online Access:	https://www.mdpi.com/1999-4923/11/7/348

Similar Items

Single-dose anti-CD138 radioimmunotherapy: bismuth-213 is more efficient than lutetium-177 for treatment of multiple myeloma in a preclinical model
by: Nolwenn eFichou, et al.
Published: (2015-11-01)

Evaluation of novel highly specific antibodies to cancer testis antigen Centrin‐1 for radioimmunoimaging and radioimmunotherapy of pancreatic cancer
by: Rubin Jiao, et al.
Published: (2019-09-01)

Mechanistic Insights into Synergy between Melanin-Targeting Radioimmunotherapy and Immunotherapy in Experimental Melanoma
by: Mackenzie E. Malo, et al.
Published: (2020-11-01)

In vitro characterisation of [177Lu]Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancer
by: Ashleigh Hull, et al.
Published: (2023-08-01)

Safety Evaluation of an Alpha-Emitter Bismuth-213 Labeled Antibody to (1→3)-β-Glucan in Healthy Dogs as a Prelude for a Trial in Companion Dogs with Invasive Fungal Infections
by: Muath Helal, et al.
Published: (2020-08-01)

First clinical experience with fractionated intracavitary radioimmunotherapy using [177Lu]Lu-6A10-Fab fragments in patients with glioblastoma: a pilot study
by: Wolfgang Roll, et al.
Published: (2023-09-01)

Lutetium 177-Labeled Cetuximab Evaluation for Radioimmunotherapeutic Applications
by: Kamal Yavari, et al.
Published: (2012-06-01)

Combination of anti-retroviral drugs and radioimmunotherapy specifically kills infected cells from HIV infected individuals
by: Dina Tsukrov, et al.
Published: (2016-09-01)

Radioimmunotherapy of Blastomycosis in a Mouse Model With a (1→3)-β-Glucans Targeting Antibody
by: Muath Helal, et al.
Published: (2020-02-01)

Targeting Melanin in Melanoma with Radionuclide Therapy
by: Kevin J. H. Allen, et al.
Published: (2022-08-01)

Inter-comparison of quantitative imaging of lutetium-177 (177Lu) in European hospitals
by: Jill Wevrett, et al.
Published: (2018-08-01)

Activity quantification and dosimetry in radiopharmaceutical therapy with reference to 177Lutetium
by: Keamogetswe Ramonaheng, et al.
Published: (2024-03-01)

Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals
by: Typhanie Ladrière, et al.
Published: (2023-04-01)

Survival and Response Outcomes for Gastrointestinal Neuroendocrine Tumor (GEP-NETs) Patients Treated with Lutetium—177-DOTATATE in a Brazilian Reference Center: A Six-Year Follow-Up Experience
by: Zenaide Silva de Souza, et al.
Published: (2023-09-01)

Development of 177Lu-phytate Complex for Radiosynovectomy
by: Hassan Yousefnia, et al.
Published: (2013-05-01)

Active bone marrow S-values for the low-energy electron emitter terbium-161 compared to S-values for lutetium-177 and yttrium-90
by: Jens Hemmingsson, et al.
Published: (2022-09-01)

Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177
by: Anton Amadeus Hörmann, et al.
Published: (2020-10-01)

Radionuclide generator-based production of therapeutic 177Lu from its long-lived isomer 177mLu
by: Rupali Bhardwaj, et al.
Published: (2019-07-01)

Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer
by: Rien Ritawidya, et al.
Published: (2023-11-01)

Optimization of 177Lu-labelling of DOTA-TOC, PSMA-I&T and FAPI-46 for clinical application
by: Aylin Cankaya, et al.
Published: (2023-05-01)

An assessment tumor targeting ability of 177Lu labeled cyclic CCK analogue peptide by binding with cholecystokinin receptor
by: Eun-Ha Cho, et al.
Published: (2016-07-01)

Therapeutic Outcomes of 177Lu-PSMA Targeted Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Single-Center Study
by: Seyed Ali Mirshahvalad, et al.
Published: (2023-01-01)

Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy
by: Anna Sundlöv, et al.
Published: (2018-07-01)

Comparative Study of the Effect of Radiation Delivered by Lutetium-177 or Actinium-225 on Anti-GD2 Chimeric Antigen Receptor T Cell Viability and Functions
by: Quaovi H. Sodji, et al.
Published: (2023-12-01)

Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial)
by: Sander C. Ebbers, et al.
Published: (2020-02-01)

The Establishment of the Enterprise Internal Control Quality Standard for No-carrier-added Lutetium ［177Lu］ Chloride Solution
by: LUO Tianwei;CHEN Mengyi;WANG Chunlin;SUN Xiangmin;YANG Liu;WANG Xiaoming;KONG Xiaohui;WU Fuhai;HUANG Xiaoyan;QIU Yanli;ZHANG Yun;LI Hongyu
Published: (2023-02-01)

Quantitative imaging for 177Lu-PSMA treatment response monitoring and dosimetry
by: Catherine Meyer, et al.
Published: (2023-12-01)

Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
by: William John Yaxley, et al.
Published: (2021-11-01)

In Vivo Measurement and Characterization of a Novel Formulation of [177Lu]-DOTA-Octreotate
by: Dale Bailey, et al.
Published: (2016-01-01)

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial
by: Bastiaan M. Privé, et al.
Published: (2020-09-01)

Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial
by: Bastiaan M. Privé, et al.
Published: (2021-11-01)

A Theranostic Approach to Imaging and Treating Melanoma with <sup>203</sup>Pb/<sup>212</sup>Pb-Labeled Antibody Targeting Melanin
by: Rubin Jiao, et al.
Published: (2023-07-01)

Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using <sup>177</sup>Lu-iPSMA and <sup>177</sup>Lu-DOTATOC: Experience after 905 Treatment Doses
by: Myrna Luna-Gutiérrez, et al.
Published: (2023-07-01)

Fully-automated synthesis of 177Lu labelled FAPI derivatives on the module modular lab-Eazy
by: Kurtulus Eryilmaz, et al.
Published: (2021-04-01)

Radionuclide Therapy of HER2-Expressing Xenografts Using [<sup>177</sup>Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab
by: Yongsheng Liu, et al.
Published: (2023-04-01)

Copper-64-Labeled 1C1m-Fc, a New Tool for TEM-1 PET Imaging and Prediction of Lutetium-177-Labeled 1C1m-Fc Therapy Efficacy and Safety
by: Judith Anna Delage, et al.
Published: (2021-11-01)

Pattern of antigen expression in metastases after radioimmunotherapy of a syngeneic rat colon carcinoma utilizing the BR96 antibody
by: Elgström Erika, et al.
Published: (2012-11-01)

Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside
by: Stephen Ahenkorah, et al.
Published: (2021-04-01)

<sup>177</sup>Lu-Labeled Iron Oxide Nanoparticles Functionalized with Doxorubicin and Bevacizumab as Nanobrachytherapy Agents against Breast Cancer
by: Evangelia-Alexandra Salvanou, et al.
Published: (2024-02-01)

Preclinical study of a new 177Lu-labeled somatostatin receptor antagonist in HT-29 human colorectal cancer cells
by: Hossein Behnammanesh, et al.
Published: (2020-07-01)